MHRA makes a promotion

Mark Birse becomes group manager, Inspections GMP/GDP

Mark Birse has been appointed as the UK Medicines and Healthcare products Regulatory Agency’s Group Manager, Inspections (Good Manufacturing Practice (GMP)/Good Distribution Practice (GDP)) following the retirement of Bryan Wright retirement at the end of March.

Birse is a chemistry graduate with an MSc in pharmaceutical sciences and he joined the MHRA in 2002. He was previously one of the MHRA’s GMP Operations Managers and was based at the Welwyn Garden City office.

Prior to this, Birse worked in the pharmaceutical industry for over 10 years in a variety of roles including production support and quality assurance and he is also eligible to be named as a Qualified Person under Directive 2001/83/EC.

In his new role, Birse will be based at the MHRA’s London head office.

You may also like

Regulatory

Biggest overhaul of trial regulation for 20 years

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners
Regulatory

MHRA joins international partnerships to set global standards for medicines and medical devices regulation

The UK is set to play a greater international role in making sure medicines and medical devices are regulated safely and efficiently worldwide, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced after being accepted as a full member of three international work-sharing partnerships
Regulatory

MHRA confirms registration of Avacta’s antigen lateral flow test

The company has ongoing commercial discussions with distributors and end user customers in countries that accept the CE mark for in vitro diagnostic products
Manufacturing

MHRA fully reinstates Bristol Labs GMP status

The company is now well-stocked for the shortages that may be brought about by Brexit
Regulatory

UK signs healthcare-focused Memorandum with Russia

The Medicines and Healthcare products Regulatory Agency has signed a Memorandum of Understanding with its Russian counterpart
Ingredients

Protak Scientific's enzymatic indicator gains MHRA support

The UK's Medicines and Healthcare products Regulatory Agency has agreed to form a focus group to discuss the use of enzymatic indicators for decontamination validation
Regulatory

UK clinical research post-Brexit

Dr Sheuli Porkess, Deputy Chief Scientific Officer of the ABPI here discusses the future of clinical research as the UK prepares to leave the EU
Subscribe now